Sustained.

The survival benefit at 4 years with nivolumab over docetaxel in patients with advanced non-small cell lung cancer. Among the relatively small group of patients with sustained response at 6 months, their 4 year overall survival rate was a whopping 56%. | Antonia, Lancet Oncol 2019